Intellia Therapeutics to Highlight Ex Vivo Genome Editing and CRISPR/Cas9 Manufacturing Advances at 2021 American Society of Hematology (ASH) Annual Meeting

CAMBRIDGE, Mass., Nov. 05, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, today announced the presentation of data from its ex vivo research and development efforts in two poster presentations at the 63^rd American Society of Hematology (ASH) Annual Meeting and Exposition, taking place in Atlanta, GA and virtually from December 11-14, 2021.

“As we continue to advance our full-spectrum strategy, we look forward to sharing preclinical data from our ex vivo platform with the research community at this year’s ASH Annual Meeting,” said Intellia Chief Scientific Officer Laura Sepp-Lorenzino, Ph.D. “The data will feature our novel allogeneic technology designed to overcome rejection by host T and NK cells without the need for host immune suppression, as well as highlight our clinical-scale manufacturing process developed for NTLA-5001, our TCR-based T cell therapeutic candidate for the treatment of acute myeloid leukemia. Together, the data support our progress toward developing engineered cell therapies with the potential to transform the lives of people living with life-threatening diseases.”

ASH Annual Meeting Poster Presentations

Title: A Novel Strategy for Off-the-shelf T Cell Therapies Evading Host T Cell and NK Cell Rejection
Abstract number: 1711
Date/Time: Saturday, December 11, 2021, 5:30 p.m. – 7:30 p.m. ET
Location: Georgia World Congress Center, Hall B5
Presenting Author: Yong Zhang, Ph.D., associate director, Cell Therapy

Title: Clinical-scale Production and Characterization of NTLA-5001 – a Novel Approach to Manufacturing CRISPR/Cas9
Abstract number: 3881
Date/Time: Monday, December 13, 2021, 6:00 p.m. – 8:00 p.m. ET
Location: Georgia World Congress Center, Hall B5

Presenting Author: Daniel Cosette, senior scientist, Process Development, Engineered T cell Therapies

Additional data collected will be included in final meeting presentations. All abstracts for the ASH Annual Meeting will be available on ASH’s website here.

About Intellia Therapeutics

Intellia Therapeutics, a leading clinical-stage genome editing company, is developing novel, potentially curative therapeutics using CRISPR/Cas9 technology. To fully realize the transformative potential of CRISPR/Cas9, Intellia is pursuing two primary approaches. The company’s in vivo programs use intravenously administered CRISPR as the therapy, in which proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia’s ex vivo programs use CRISPR to create the therapy by using engineered human cells to treat cancer and autoimmune diseases. Intellia’s deep scientific, technical and clinical development experience, along with its robust intellectual property portfolio, have enabled the company to take a leadership role in harnessing the full potential of CRISPR/Cas9 to create new classes of genetic medicine. Learn more at intelliatx.com. Follow us on Twitter @intelliatweets.

Forward-Looking Statements

This press release contains “forward-looking statements” of Intellia Therapeutics, Inc. (“Intellia” or the “Company”) within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, express or implied statements regarding Intellia’s beliefs and expectations regarding its: advancement and expansion of its CRISPR/Cas9 technology to develop human therapeutic products, as well as its ability to maintain and expand its related intellectual property portfolio; expectations of the potential impact of the coronavirus disease 2019 pandemic on strategy, future operations and timing of its clinical trials or IND submissions; and statements regarding the timing of regulatory filings regarding its development programs.

Any forward-looking statements in this press release are based on management’s current expectations and beliefs of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: risks related to Intellia’s ability to protect and maintain its intellectual property position; risks related to Intellia’s relationship with third parties, including its licensors and licensees; risks related to the ability of its licensors to protect and maintain their intellectual property position; uncertainties related to the authorization, initiation and conduct of studies and other development requirements for its product candidates; the risk that any one or more of Intellia’s product candidates will not be successfully developed and commercialized; and the risk that the results of preclinical studies or clinical studies will not be predictive of future results in connection with future studies. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause Intellia’s actual results to differ from those contained in the forward-looking statements, see the section entitled “Risk Factors” in Intellia’s most recent annual report on Form 10-K as well as discussions of potential risks, uncertainties, and other important factors in Intellia’s other filings with the Securities and Exchange Commission (“SEC”). All information in this press release is as of the date of the release, and Intellia undertakes no duty to update this information unless required by law.

Intellia Contacts:

Investors:
Ian Karp
Senior Vice President, Investor Relations and Corporate Communications
+1-857-449-4175
ian.karp@intelliatx.com

Lina Li
Director, Investor Relations
+1-857-706-1612
lina.li@intelliatx.com

Media:
Matt Crenson
Ten Bridge Communications
+1-917-640-7930
media@intelliatx.com
mcrenson@tenbridgecommunications.com